Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 28Gastrointestinal 9Genitourinary 6Tumor-Agnostic 5Breast 5Dermatologic 4Lymphoid 3CNS 3Gynecologic 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Ovarian Neoplasms 17Uterine Cervical Neoplasms 9Endometrial Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Fallopian Tube Neoplasms 4Carcinoma, Ovarian Epithelial 4Uterine Neoplasms 3Pancreatic Neoplasms 3Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Genital Neoplasms, Female 2Esophageal Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Dysplasia 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Trophoblastic Neoplasms 1Triple Negative Breast Neoplasms 1Thymus Neoplasms 1Thymoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Neoplasms 1Peritoneal Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1

Interventions

pembrolizumab 22Paclitaxel 14Cyclophosphamide 13Carboplatin 11Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 9fludarabine 8Nivolumab 7Leucovorin 7Gemcitabine 7Fluorouracil 7Doxorubicin 7aldesleukin 6Oxaliplatin 6liposomal doxorubicin 5Topotecan 5Taxes 5Irinotecan 5Interleukin-2 5Cisplatin 5olaparib 4atezolizumab 4Hyperthermic Intraperitoneal Chemotherapy 4Drug Therapy 4seribantumab 3fludarabine phosphate 3durvalumab 3dostarlimab 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Pemetrexed × Gynecologic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡